Morphological changes of pancreatic endocrinocytes on the background of medical treatment of diabetes mellitus by exenatid and insulin

Authors

DOI:

https://doi.org/10.26641/1997-9665.2020.3.132-136

Keywords:

endocrinocytes, pancreatic islet, experimental diabetes mellitus, treatment, rats

Abstract

Background. The morphological changes of the pancreas, which developed in experimental diabetes and its treatment with insulin and exenatide, where the long injection morphologically revealed improving carbohydrate metabolism and increased regenerative processes in islets of the pancreas that were studied. Objective: the aim of the study was to evaluate the morphological changes of pancreatic endocrinocytes against the background of drug treatment of diabetes with exenatide and insulin in rats. Methods. Absolute insulin deficiency, corresponding Type I diabetes was modeled in animals. Treatment was started from the 14th day of induced diabetes development. Collection of samples was performed on the 56th and the 70th days of the experiment. Results. The increase in compensatory restorative processes in the islets was noted. In the treatment with Exenatid and insulin simultaneously, histologically manifested as partial restoration of typical ultrastructural arrangement of endocrinocytes and also the appearance of “ductal” beta cells, acinarislet cells in the exocrine parenchyma, the increase of ratio of beta and alpha cells and the increase islet’s area were noted. Conclusion. The proof of this is the increase in the average area of the islands, the relationship of betta cells / alpha cells during the experiment and partial reconstruction of typical ultrastructural endocrinocytes of pancreatic islands.

References

  1. Kim BM, Ham YM, Shin YJ, Min DN, Park IS. Clustern expression during regeneration of pancreatic islet β-cell in streptosotozin-induced diabetic rats. Diabetologia. 2001;44(12):2192-202. https://doi.org/10.1007/s001250100029
  2. Li X-G, Li L, Zhou X, Chen Y, Ren Y-P, Zhou T-Y, Lu W. Pharmacokinetic/ pharmacodynamic studies on exenatide in diabetic rats. Acta Pharmacologica Sinica. 2012;33(11):1379-1386. https://doi.org/10.1038/aps.2012.33
  3. Tabák AG, Anderson J, Aschner P, Liu М, Saremi A, Stella P, Tinahones FJ, Wysham C, Meier JJ. Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared With Basal-Bolus Regimen in Patients With Type 2 Diabetes: Propensity Score Matched Analysis. Diabetes Ther. 2020;11(1):305–318. https://doi.org/10.1007/s13300-019-00735-7
  4. Porcellatti F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB. Better long term glycemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal–time lispro insulin. Diabet. Med. 2004;21(11):1213-1220. https://doi.org/10.1111/j.1464-5491.2004.01323.x
  5. Ivantsiv OR. Morphometric characteristic of the pancreatic islets in thtreatment of eхperimental diabetes with insulin. The Pharma Innovation Journal. 2016;5(4):80-83.

Downloads

How to Cite

Ivantsiv, O. R. (2020). Morphological changes of pancreatic endocrinocytes on the background of medical treatment of diabetes mellitus by exenatid and insulin. Морфологія / Morphologia / Morfologìâ, 14(3), 132–136. https://doi.org/10.26641/1997-9665.2020.3.132-136

Issue

Section

Статті